Basilea’s cancer pipeline slimdown continues; Aquestive looks to outlicense seizure drug in US
In February, Swiss biopharma Basilea announced an unusual move — it was looking to ditch its oncology assets in favor of its infectious disease pipeline. And over the past year, it has executed that plan, returning some cancer candidates and pawning off others.
In its latest move, Basilea will be selling its preclinical CLK kinase inhibitors to Massachusetts-based Twentyeight-Seven Therapeutics. Twentyeight-Seven will pay Basilea CHF 1 million (roughly $1 million USD) upfront. Near-term milestones total CHF 2 million, and total downstream milestones reach up to CHF 351 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
